Zoya Demidenko: Scientist in Oncology Studies Zoya Demidenko is a recognized scholar affiliated with the Division of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a strong background in clinical investigation.
Her scholarly work spans a number of critical areas, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, cellular aging, and cancer science. As of now, she has co-authored over 46 scientific publications, which have accumulated over 4,100 citations — a testament to the significance of her work.
Among her most significant contributions involves explaining the pathways of cell aging. Her studies demonstrated that when the cell cycle is blocked but cellular growth proceeds, cells experience senescence. Crucially, Zoya Demidenko established that this transition is inhibited by medication using substances such as rapamycin. Zoya Demidenko has also added considerably to cancer treatment research, notably in the area of selective cell protection — a strategy intended to shielding healthy tissue from cytotoxic treatment while leaving tumor cells vulnerable. This approach offers significant hope for lowering the toxic effects of cancer treatment.
Throughout her scientific life, Demidenko has collaborated with leading scientists internationally, among them Dr. Mikhail Blagosklonny. Her research can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko ranks as a widely cited voice in contemporary oncological research, with her discoveries continue to guide our knowledge of the way biological cells age, interact with therapy, and the ways in which cancer might be more effectively combated. https://www.aging-us.com/article/100421/
Zoya Demidenko: Scientist in Oncology Studies
Zoya Demidenko is a recognized scholar affiliated with the Division of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a strong background in clinical investigation.
Her scholarly work spans a number of critical areas, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, cellular aging, and cancer science. As of now, she has co-authored over 46 scientific publications, which have accumulated over 4,100 citations — a testament to the significance of her work.
Among her most significant contributions involves explaining the pathways of cell aging. Her studies demonstrated that when the cell cycle is blocked but cellular growth proceeds, cells experience senescence. Crucially, Zoya Demidenko established that this transition is inhibited by medication using substances such as rapamycin.
Zoya Demidenko has also added considerably to cancer treatment research, notably in the area of selective cell protection — a strategy intended to shielding healthy tissue from cytotoxic treatment while leaving tumor cells vulnerable. This approach offers significant hope for lowering the toxic effects of cancer treatment.
Throughout her scientific life, Demidenko has collaborated with leading scientists internationally, among them Dr. Mikhail Blagosklonny. Her research can be found in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
1.03.2026 11:21] Папа: With an h-index of 33, Zoya Demidenko ranks as a widely cited voice in contemporary oncological research, with her discoveries continue to guide our knowledge of the way biological cells age, interact with therapy, and the ways in which cancer might be more effectively combated.
https://www.aging-us.com/article/100421/
sweet bonanza spei 2026 sweet bonanza spei 2026
плинко пополнение с карты Казахстан http://plinko50862.help
pin-up rasmiy sayt http://pinup52914.help
1win авиатор 1win авиатор